Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2)
The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: This study compared the efficacy and safety of once-weekly dulaglutide, a glucagon-like peptide-1 receptor agonist, with daily insulin glargine, both combined with maximally tolerated doses of metformin and glimepiride in patients with type 2 diabetes. The primary objective was noninferiority of dulaglutide 1.5 mg to glargine in the HbA1c change from baseline at 52 weeks. RESEARCH DESIGN AND METHODS: In this 78-week, open-label study, 810 patients were randomized to dulaglutide 1.5 mg, dulaglutide 0.75 mg, or glargine. RESULTS: The baseline mean ± SD HbA1c was 8.1 ± 1.0% (65.5 ± 10.8 mmol/mol). The least squares mean ± SE HbA1c change from baseline to the primary end point was −1.08 ± 0.06% (−11.8 ± 0.7 mmol/mol) for dulaglutide 1.5 mg, −0.76 ± 0.06% (−8.3 ± 0.7 mmol/mol) for dulaglutide 0.75 mg, and −0.63 ± 0.06% (−6.9 ± 0.7 mmol/mol) for glargine, with an end point mean ± SD dose of 29 ± 26 units (0.33 ± 0.24 units/kg), and a fasting plasma glucose (mean ± SD) of 118 ± 23 mg/dL from self-monitored plasma glucose. Statistical criteria for superiority were met with dulaglutide 1.5 mg and for noninferiority with dulaglutide 0.75 mg. More patients on dulaglutide 1.5 mg achieved HbA1c targets <7.0% (53 mmol/mol) versus glargine (P < 0.001). Body weight decreased with dulaglutide and increased with glargine. Total hypoglycemia rates were lower with dulaglutide; severe hypoglycemia was minimal. Increases in pancreatic enzymes were observed for dulaglutide. Incidence of nausea (15.4, 7.7, and 1.5%) and diarrhea (10.6, 9.2, and 5.7%) were more common with dulaglutide 1.5 mg and 0.75 mg than with glargine. CONCLUSIONS: Once-weekly dulaglutide 1.5 mg, compared with daily insulin glargine without forced titration, demonstrated greater HbA1c reduction and weight loss, with a higher incidence of gastrointestinal adverse events and a lower risk of hypoglycemia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“GLP-1 RAs and dual GIP and GLP-1 RA in these trials also had a lower risk of hypoglycemia and beneficial effects on body weight compared with insulin, albeit with greater gastrointestinal side effects.”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [127]
In the citing paper
“In trials analyzing the addition of an injectable GLP-1 RA, dual GIP and GLP-1 RA, or insulin in people needing further glucose lowering, glycemic efficacies of GLP-1 RAs and the dual GIP and GLP-1 RA were similar to or greater than that of basal insulin (123-130).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [127]
In the citing paper
“GLP-1 RAs and dual GIP and GLP-1 RA in these trials also had a lower risk of hypoglycemia and beneficial effects on body weight compared with insulin, albeit with greater gastrointestinal side effects.”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [127]
In the citing paper
“GLP-1 RAs and dual GIP and GLP-1 RA in these trials also had a lower risk of hypoglycemia and beneficial effects on body weight compared with insulin, albeit with greater gastrointestinal side effects.”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [127]
In the citing paper
“It is worth mentioning that in the AWARD-2 study, there were several cases of pancreatitis caused by DUL (112).”
From GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach (2023) · cites this paper as [112]
Citations
Cites
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066
Resampling-Based Multiple Testing: Examples and Methods for p-Value Adjustment.
Martin, M. A., Westfall, P. H., & Young, S. S. (1994) · Biometrics · doi:10.2307/2533464 · Cited by 1,699 · cited 11×
“%) at least once after baseline; dulaglutide-neutralizing antibodies developed in 5, but no native sequence GLP-1neutralizing–antibodies developed.”
BackgroundInfluentialRiddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
Pathogenesis of type 2 diabetes mellitus
DeFronzo, R. A. (2004) · Medical Clinics of North America · doi:10.1016/j.mcna.2004.04.013 · Cited by 1,342
Defining and Reporting Hypoglycemia in Diabetes
American Diabetes Association Workgroup on Hypoglycemia (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1245 · Cited by 1,146
on behalf of the Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group, Russell-Jones, D., Vaag, A., Schmitz, O., Sethi, B. K., Lalic, N., Antic, S., Zdravkovic, M., Ravn, G. M., & Simó, R. (2009) · Diabetologia · doi:10.1007/s00125-009-1472-y · Cited by 835
Heine, R. J., Van Gaal, L. F., Johns, D., Mihm, M. J., Widel, M. H., Brodows, R. G., & for the GWAA Study Group* (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-8-200510180-00006 · Cited by 795
Pratley, R. E., Nauck, M., Bailey, T., Montanya, E., Cuddihy, R., Filetti, S., Thomsen, A. B., Søndergaard, R. E., & Davies, M. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60307-8 · Cited by 586
Resampling-Based Multiple Testing: Examples and Methods for p-Value Adjustment.
Thomas, G. E., Westfall, P. H., & Young, S. S. (1994) · The Statistician · doi:10.2307/2348369 · Cited by 513
Cited by
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s009 · Cited by 1,555
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s009 · Cited by 972
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s009 · Cited by 851
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Bajaj, M., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s009 · Cited by 728
Del Prato, S., Kahn, S. E., Pavo, I., Weerakkody, G. J., Yang, Z., Doupis, J., Aizenberg, D., Wynne, A. G., Riesmeyer, J. S., Heine, R. J., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)02188-7 · Cited by 684
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Gaglia, J. L., Hilliard, M. E., Johnson, E. L., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s009 · Cited by 662
Ludvik, B., Giorgino, F., Jódar, E., Frias, J. P., Fernández Landó, L., Brown, K., Bray, R., & Rodríguez, Á. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01443-4 · Cited by 639
Self-citationAroda, V. R., Bain, S. C., Cariou, B., Piletič, M., Rose, L., Axelsen, M., Rowe, E., & DeVries, J. H. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30085-2 · Cited by 464
Rosenstock, J., Allison, D., Birkenfeld, A. L., Blicher, T. M., Deenadayalan, S., Jacobsen, J. B., Serusclat, P., Violante, R., Watada, H., Davies, M., et al. (2019) · JAMA · doi:10.1001/jama.2019.2942 · Cited by 421
Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus
Tahrani, A. A., Barnett, A. H., & Bailey, C. J. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.86 · Cited by 398
A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond
Prasad-Reddy, L., & Isaacs, D. (2015) · Drugs in Context · doi:10.7573/dic.212283 · Cited by 365
9. pharmacologic approaches to glycemic treatment: standards of care in diabetes—2026
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s009 · Cited by 263
Ludvik, B., Frías, J. P., Tinahones, F. J., Wainstein, J., Jiang, H., Robertson, K. E., García-Pérez, L.-E., Woodward, D. B., & Milicevic, Z. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30023-8 · Cited by 266
Aroda, V. R. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13162 · Cited by 253
GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach
Wang, J.-Y., Wang, Q.-W., Yang, X.-Y., Yang, W., Li, D.-R., Jin, J.-Y., Zhang, H.-C., & Zhang, X.-F. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1085799 · Cited by 248
“DUL is a long-acting GLP-1R agonist which can promote insulin secretion, inhibit gastric emptying, and reduce appetite.”
BackgroundInfluentialGlucagon‐like peptide‐1 receptor agonists in type 2 diabetes treatment: are they all the same?
Gentilella, R., Pechtner, V., Corcos, A., & Consoli, A. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3070 · Cited by 227
Self-citation2021 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association
Hur, K. Y., Moon, M. K., Park, J. S., Kim, S.-K., Lee, S.-H., Yun, J.-S., Baek, J. H., Noh, J., Lee, B.-W., Oh, T. J., et al. (2021) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2021.0156 · Cited by 226
Pharmacotherapy of type 2 diabetes: An update
Upadhyay, J., Polyzos, S. A., Perakakis, N., Thakkar, B., Paschou, S. A., Katsiki, N., Underwood, P., Park, K.-H., Seufert, J., Kang, E. S., et al. (2018) · Metabolism · doi:10.1016/j.metabol.2017.08.010 · Cited by 187
Battle of GLP-1 delivery technologies
Yu, M., Benjamin, M. M., Srinivasan, S., Morin, E. E., Shishatskaya, E. I., Schwendeman, S. P., & Schwendeman, A. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.07.009 · Cited by 180
The Role of Glucagon in the Pathophysiology and Treatment of Type 2 Diabetes
Hædersdal, S., Lund, A., Knop, F. K., & Vilsbøll, T. (2018) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.12.003 · Cited by 162
Jendle, J., Grunberger, G., Blevins, T., Giorgino, F., Hietpas, R. T., & Botros, F. T. (2016) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2810 · Cited by 158
“The maximal reduction in mean FBG was achieved by 2 weeks for both dulaglutide doses [38].”
BackgroundMethodInfluentialSelf-citationAbd El Aziz, M. S., Kahle, M., Meier, J. J., & Nauck, M. A. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12804 · Cited by 155
Safety and tolerability of once‐weekly GLP‐1 receptor agonists in type 2 diabetes
Trujillo, J. (2020) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13225 · Cited by 130
“75 mg 280 47 (17)* 17 (6)* 26 (9) 4 (1) Exenatide BID 10 μg 276 77 (28) 33 (12) 21 (8) 10 (4) AWARD-228 Dulaglutide QW 1.”
Hu, W., Song, R., Cheng, R., Liu, C., Guo, R., Tang, W., Zhang, J., Zhao, Q., Li, X., & Liu, J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.927859 · Cited by 127
“, 2015 (45) NCT01075282 78 Dulaglutide Glargine 1/545 0/262 56.”
Tirzepatide for the treatment of adults with type 2 diabetes: An endocrine perspective
De Block, C., Bailey, C., Wysham, C., Hemmingway, A., Allen, S. E., & Peleshok, J. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14831 · Cited by 121
“Gastrointestinal side effects were also reported more frequently than insulin glargine 100 U/ml with GLP-1 receptor agonists.(94,98,99) Consistent with the low rate of study treatment discontinuation, ≤3% of participants who received at least one dose of tirzepatide discontinued treatment because of either nausea, vom…”
BackgroundSilverii, G. A., Monami, M., Gallo, M., Ragni, A., Prattichizzo, F., Renzelli, V., Ceriello, A., & Mannucci, E. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15382 · Cited by 113
Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research
Levin, P. A., Nguyen, H., Wittbrodt, E., & Kim, S. C. (2017) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s130834 · Cited by 107
Targeting the incretin system in obesity and type 2 diabetes mellitus
Ansari, S., Khoo, B. C. E., & Tan, T. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-00979-9 · Cited by 127
“Compared with baseline, dulaglutide at a dose of 1.5 mg once weekly lowered HbA 1c by 0.8–1.6% after 26 weeks 72–77 or 104 weeks 78 , and this mean reduction was superior to oral (metformin 72 , glimepiride 74 ) and injectable (exenatide 75 , insulin glargine 76,77 ) glucose-lowering medications.”
InfluentialTran, K., Park, Y. I., Pandya, S., Muliyil, N. J., Jensen, B. D., Huynh, K., & Nguyen, Q. P. H. (2017) · PubMed · Cited by 124
Singh, S., Wright, E. E., Kwan, A. Y. M., Thompson, J. C., Syed, I. A., Korol, E. E., Waser, N. A., Yu, M. B., & Juneja, R. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12805 · Cited by 101
Dungan, K. M., Weitgasser, R., Perez Manghi, F., Pintilei, E., Fahrbach, J. L., Jiang, H. H., Shell, J., & Robertson, K. E. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12634 · Cited by 99
Cao, C., Yang, S., & Zhou, Z. (2019) · Endocrine · doi:10.1007/s12020-019-02055-z · Cited by 99
Gallwitz, B., Dagogo‐Jack, S., Thieu, V., Garcia‐Perez, L., Pavo, I., Yu, M., Robertson, K. E., Zhang, N., & Giorgino, F. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13086 · Cited by 98
Self-citationEffects of dulaglutide on alcohol consumption during smoking cessation
Probst, L., Monnerat, S., Vogt, D. R., Lengsfeld, S., Burkard, T., Meienberg, A., Bathelt, C., Christ-Crain, M., & Winzeler, B. (2023) · JCI Insight · doi:10.1172/jci.insight.170419 · Cited by 94
Mody, R., Huang, Q., Yu, M., Zhao, R., Patel, H., Grabner, M., & Landó, L. F. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13603 · Cited by 93
Kellerer, M., Kaltoft, M. S., Lawson, J., Nielsen, L. L., Strojek, K., Tabak, Ö., & Jacob, S. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14765 · Cited by 107
“This reflects the known effects of GLP-1RAs and insulins on BW previously shown in other randomized clinical trials, with GLP-1RAs associated with weight loss and insulins with weight gain.(16,34,35) In our study, decreases in systolic blood pressure were observed with semaglutide, in accordance with previous studies…”
ResultZaccardi, F., Htike, Z. Z., Webb, D. R., Khunti, K., & Davies, M. J. (2016) · Annals of Internal Medicine · doi:10.7326/m15-1432 · Cited by 91
Do GLP-1 Receptor Agonists Increase the Risk of Breast Cancer? A Systematic Review and Meta-analysis
Piccoli, G. F., Mesquita, L. A., Stein, C., Aziz, M. M., Zoldan, M., Degobi, N. A. H., Spiazzi, B. F., Junior, G. L. L., Colpani, V., & Gerchman, F. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa891 · Cited by 99
Yang, Y., He, L., Han, S., Yang, N., Liu, Y., Wang, X., Li, Y., Ping, F., Xu, L., Li, W., et al. (2025) · Journal of Diabetes · doi:10.1111/1753-0407.70063 · Cited by 108
Nreu, B., Dicembrini, I., Tinti, F., Sesti, G., Mannucci, E., & Monami, M. (2020) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2020.03.013 · Cited by 89
Araki, E., Inagaki, N., Tanizawa, Y., Oura, T., Takeuchi, M., & Imaoka, T. (2015) · Diabetes, obesity and metabolism · doi:10.1111/dom.12540 · Cited by 83
The effects of dual GLP-1/GIP receptor agonism on glucagon secretion-A Review
Mathiesen, D. S., Bagger, J. I., Bergmann, N. C., Lund, A., Christensen, M. B., Vilsbøll, T., & Knop, F. K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174092 · Cited by 80
Lee, S.-A., & Lee, D.-Y. (2017) · Annals of Pediatric Endocrinology & Metabolism · doi:10.6065/apem.2017.22.1.15 · Cited by 70
Adetunji, O., Kalra, S., Baruah, M., Sahay, R. K., Unnikrishnan, A., & Uppal, S. (2016) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.176351 · Cited by 82
Shestakova, M. V., & Александровна, Ю. Е. (2015) · Diabetes Mellitus · doi:10.14341/dm20151s1-112 · Cited by 71
“Динамика постпрандиальной гликемии к первичной конечной точке в исследованиях AWARD 1, 2 и 4 была статистически значимо большей в сравнении с плацебо или препаратами сравнения: эксенатидом и инсулином гларгин [28, 29, 32].”
GLP ‐1 receptor agonists and the risk for cancer: A meta‐analysis of randomized controlled trials
Silverii, G. A., Marinelli, C., Bettarini, C., Del Vescovo, G. G., Monami, M., & Mannucci, E. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.16489 · Cited by 67
A Comprehensive Review on Weight Loss Associated with Anti-Diabetic Medications
Haddad, F., Dokmak, G., Bader, M., & Karaman, R. (2023) · Life · doi:10.3390/life13041012 · Cited by 78
“75 mg of dulaglutide once a week or daily insulin glargine [148].”
BackgroundMethodPozzilli, P., Leslie, R. D., Peters, A. L., Buzzetti, R., Shankar, S. S., Miličević, Z., Pavo, I. J., Lebrec, J., Martin, S., & Schloot, N. C. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13237 · Cited by 76
Central GLP-1 receptors: Novel molecular targets for cocaine use disorder
Hernandez, N. S., & Schmidt, H. D. (2019) · Physiology & Behavior · doi:10.1016/j.physbeh.2019.03.026 · Cited by 70
NREU, B., DICEMBRINI, I., TINTI, F., MANNUCCI, E., & MONAMI, M. (2023) · Minerva Endocrinology · doi:10.23736/s2724-6507.20.03219-8 · Cited by 63
Drake, T. C., Landsteiner, A. M. K., Langsetmo, L., MacDonald, R. H., Anthony, M., Kalinowski, C., Ullman, K. E., Billington, C. J., Kaka, A. S., Sultan, S., et al. (2024) · Annals of Internal Medicine · doi:10.7326/m23-1490 · Cited by 74
Ferdinand, K. C., Botros, F. T., Atisso, C. M., & Sager, P. T. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0355-z · Cited by 61
Odawara, M., Miyagawa, J., Iwamoto, N., Takita, Y., Imaoka, T., & Takamura, T. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12602 · Cited by 56
Peptibodies: An elegant solution for a long‐standing problem
Cavaco, M. C., Castanho, M. A. R. B., & Neves, V. (2017) · Peptide Science · doi:10.1002/bip.23095 · Cited by 63
Kalra, S., Das, A. K., Sahay, R. K., Baruah, M. P., TIWASKAR, M. H., Das, S., Chatterjee, S., Saboo, B., Bantwal, G., Bhattacharya, S., et al. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0669-4 · Cited by 70
Li, H., Chen, J., Li, B., & Fang, X. (2020) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2020.108968 · Cited by 56
Janež, A., Muzurović, E. M., Bogdański, P., Czupryniak, L., Fábryová, Ľ., Fras, Z., Guja, C., Haluzík, M., Kempler, P., Lalic, N. M., et al. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01615-5 · Cited by 69
“HbA1c decrease was − 1.36 ± 0.08% versus exenatide BID in AWARD‑1 trial and − 1.08 ± 0.06% versus insulin glargine in the AWARD‑2 trial [153–155].”
BackgroundInfluentialCardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists
Kang, Y. M., & Jung, C. H. (2016) · Endocrinology and Metabolism · doi:10.3803/enm.2016.31.2.258 · Cited by 51
“Dulaglutide Wysham et al. (2014) [80] (AWARD-1) 52 976 (Met±TZD) +(exenatide BID or placebo →dulaglutide at week 26) 0.75 mg/day –0.20a 1.56 (2.80a at week 26) 1.62 (–0.36a at week 26) –0.09 TC –0.08 LDL-C 0.00 HDL-C 0.04 TG 1.5 mg/day –1.30a 1.68 (2.80a at week 26) 0.83 (0.11a at week 26) –0.12 TC –0.06 LDL-C 0.05 HD…”
InfluentialDulaglutide: A Review in Type 2 Diabetes
Scott, L. J. (2020) · Drugs · doi:10.1007/s40265-020-01260-9 · Cited by 56
Wang, W.-Q., Nevárez, L., Filippova, E., Song, K., Tao, B., Gu, L., Wang, F., Li, P.-F., & Yang, J. (2018) · Diabetes, obesity and metabolism · doi:10.1111/dom.13506 · Cited by 47
“studies, the present study seemed to include higher mean PPG and greater PPG excursions at baseline (Figure 2E) compared with the AWARD-2 study.(8) For example, the morning 2-hour PPG and glucose excursions in the present study at randomization were ~13 and ~4 mmol/L, compared with ~11 and ~2 mmol/L in the AWARD-2 stu…”
ResultZhang, Y., Chen, G., Wang, W., Yang, D., Zhu, D., & Jing, Y. (2024) · Bone · doi:10.1016/j.bone.2024.117338 · Cited by 52
Glucagon-like polypeptide agonists in type 2 diabetes mellitus: efficacy and tolerability, a balance
Tella, S., & Rendell, M. (2015) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018815580257 · Cited by 55
Frías, J. P., Wynne, A. G., Matyjaszek‐Matuszek, B., Bartášková, D., Cox, D. A., Woodward, B., Li, Y. G., Tham, L. S., & Miličević, Z. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13764 · Cited by 50
Matza, L. S., Boye, K. S., Stewart, K. D., Coyne, K. S., Wullenweber, P. K., Cutts, K. N., Jordan, J. B., Wang, Q., Yu, M. B., Currie, B. M., et al. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13902 · Cited by 47
Hu, M., Cai, X., Yang, W., Zhang, S., Nie, L., & Ji, L. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.015323 · Cited by 48
Boustani, M. A., Pittman, I., Yu, M., Thieu, V. T., Varnado, O. J., & Juneja, R. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12687 · Cited by 46
“Given the heterogeneity of concomitant therapy across the AWARD clinical trial programme, with concomitant sulphonylurea and insulin therapy increasing the risk of hypoglycaemia (AWARD 2 and 4) [16,27,28,32] and pioglitazone attenuating weight loss (AWARD 1) [29,31], pooling of all studies would not have been the best…”
BackgroundLong-acting GLP-1RAs: An overview of efficacy, safety, and their role in type 2 diabetes management
Chun, J. H., & Butts, A. (2020) · JAAPA · doi:10.1097/01.jaa.0000669456.13763.bd · Cited by 45
GLP-1 as a target for therapeutic intervention
Rajeev, S. P., & Wilding, J. P. H. (2016) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2016.08.005 · Cited by 45
Chen, Y. H., Huang, C., Cho, Y. M., Li, P., Gu, L., Wang, F., Yang, J., & Wang, W. Q. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13340 · Cited by 43
Kang, S., Kang, S. M., Choi, J. H., Ko, S., Koo, B. K., Kwon, H.-S., Kim, M. K., Kim, S. Y., Kim, S., Kim, Y., et al. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0469 · Cited by 83
Dulaglutide for the treatment of type 2 diabetes
Scheen, A. J. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1296131 · Cited by 48
Guerci, B., Charbonnel, B., Gourdy, P., Hadjadj, S., Hanaire, H., Marre, M., & Vergès, B. (2019) · Diabetes & Metabolism · doi:10.1016/j.diabet.2019.01.006 · Cited by 40
Consoli, A., Formoso, G., BALDASSARRE, M. P. A., & Febo, F. (2018) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2018.1428305 · Cited by 44
Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review
Østergaard, L., Frandsen, C. S., & Madsbad, S. (2016) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2016.1121808 · Cited by 38
“001, dulaglutide groups compared with the insulin group).[99] In the AWARD-4 study, patients (baseline”
BackgroundFederici, M. O., McQuillan, J., Biricolti, G., Losi, S., Lebrec, J., Richards, C., Miglio, C., & Norrbacka, K. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0396-2 · Cited by 37
“There are several GLP-1 RAs on the market in Europe, each with specific characteristics [3]; they vary in the magnitude of their effect in reducing HbA1c and enhancing weight loss and also in their adverse event profiles [3, 8].”
BackgroundMirabelli, M., CHIEFARI, E. D., Tocci, V., Caroleo, P., Giuliano, S., Greco, E. A., Luque, R. M., Puccio, L., FOTI, D. P., Aversa, A., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10050985 · Cited by 39
“5 mg/once weekly has been compared to insulin when treatment with a combination of MET and a sulfonylurea was insufficient to control T2D in the open-label trial AWARD-2 [13].”
BackgroundMethodResultInfluentialArredouani, A. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108824 · Cited by 36
Umpierrez, G. E., Pantalone, K. M., Kwan, A. Y. M., Zimmermann, A. G., Zhang, N., & Landó, L. F. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12660 · Cited by 36
“with insulin lispro, with or without metformin [16], and similar reductions compared with insulin glargine added on to metformin and sulphonylurea [15].”
BackgroundSelf-citationPharmacotherapy of ‘treatment resistant’ type 2 diabetes
Scheen, A. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1297424 · Cited by 34
Long-term management of type 2 diabetes with glucagon-like peptide-1 receptor agonists
Courtney, H., Nayar, R., Rajeswaran, C., & Jandhyala, R. (2017) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s126763 · Cited by 38
“9 One case each of acute and chronic pancreatitis was diagnosed in the dulaglutide 1.5 mg group in AWARD-2.”
BackgroundInfluentialMilicevic, Z., Anglin, G., Harper, K., Konrad, R. J., Skrivanek, Z., Glaesner, W., Karanikas, C. A., & Mace, K. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12640 · Cited by 32
Nauck, M. A., Mirna, A. E. A., & Quast, D. R. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14988 · Cited by 32
“…RAs Aroda et al. 2017 b Aroda et al. 2017 a Weissman et al. 2014 Wang et al. 2018 b Wang et al. 2018 a Araki et al. 2015 Giorgino et al. 2015 b Giorgino et al. 2015 a Davies et al. 2013 Inagaki et al. 2012 Diamant et al. 2010 Guo et al. 2020 Yan et al. 2019 D'Alessio et al. 2015 Gough et al.…”
BackgroundInfluentialAlkhouri, N., Charlton, M., Gray, M. E., & Noureddin, M. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2473062 · Cited by 34
Tseng, P., Zeng, B., Hsu, C.-W., Hung, C., Carvalho, A. F., Stubbs, B., Chen, Y., Chen, T., Lei, W., Chen, J.-J., et al. (2025) · BMC Medicine · doi:10.1186/s12916-025-04018-w · Cited by 36
Unlocking the multifaceted roles of GLP-1: Physiological functions and therapeutic potential
AL-Noshokaty, T. M., Abdelhamid, R., Abdelmaksoud, N. M., Khaled, A., Hossam, M., Ahmed, R., Saber, T., Khaled, S., Elshaer, S. S., & Abulsoud, A. I. (2025) · Toxicology Reports · doi:10.1016/j.toxrep.2025.101895 · Cited by 30
“In the AWARD-2 study, Dulaglutide caused numerous pancreatitis episodes [283].”
Wang, H., Liu, Y., Tian, Q., Yang, J., Lu, R., Zhan, S., Haukka, J. K., & Hong, T. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13177 · Cited by 36
Emoto, M., Terauchi, Y., Ozeki, A., Oura, T., Takeuchi, M., & Imaoka, T. (2015) · Endocrine Journal · doi:10.1507/endocrj.ej15-0401 · Cited by 29
Yajima, T., Yajima, K., Hayashi, M., Takahashi, H., & Yasuda, K. (2017) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2017.12.005 · Cited by 29
Dulaglutide: A Review in Type 2 Diabetes
Burness, C. B., & Scott, L. J. (2015) · BioDrugs · doi:10.1007/s40259-015-0143-4 · Cited by 33
“4 % b Fasting serum [18, 20, 22, 23, 25] or plasma [19, 21] glucose; some values converted from mg/dL to mmol/L (mg/dL 9 0.”
BackgroundMethodInfluentialKassem, S., Khalaila, B., Stein, N., Saliba, W., & Zaina, A. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15828 · Cited by 28
Matza, L. S., Boye, K. S., Currie, B. M., Paczkowski, R., Landó, L. F., Mody, R., & Jordan, J. B. (2018) · Current Medical Research and Opinion · doi:10.1080/03007995.2018.1465903 · Cited by 28
Yu, M., Brunt, K. V., Varnado, O. J., & Boye, K. S. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12624 · Cited by 31
“Lower total hypoglycaemia rates were observed with dulaglutide; events of severe hypoglycaemia were minimal [9].”
BackgroundInfluentialOrme, M., Nguyen, H., Lu, J. Y., & Thomas, S. (2017) · Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy · doi:10.2147/dmso.s116810 · Cited by 26
Dulaglutide (LY-2189265) for the treatment of type 2 diabetes
Scheen, A. J. (2016) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2016.1141046 · Cited by 28
Glucagon-like peptide-1 receptor agonists in neurodegenerative diseases: Promises and challenges
Zhou, Z., Yi, L., Popławska-Domaszewicz, K., Chaudhuri, К. R., Jankovic, J. J., & Tan, E. K. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107770 · Cited by 35
Ren, X., Hua, H., Wu, Y., Zhang, W., Long, X., Bai, Y., & Cheng, N. (2025) · Scientific Reports · doi:10.1038/s41598-025-09807-0 · Cited by 38
Pratley, R. E., Aroda, V. R., Catarig, A., Lingvay, I., Lüdemann, J., Yildirim, E., & Viljoen, A. (2020) · BMJ Open · doi:10.1136/bmjopen-2020-037883 · Cited by 31
Effects of GLP-1 Agonists on mortality and arrhythmias in patients with Type II diabetes
Al‐Sadawi, M., Aslam, F. M., Tao, M., Alsaiqali, M., Almasry, I. O., Fan, R., Rashba, E. J., & Singh, A. (2023) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2023.101218 · Cited by 34
“AWARD-2 [30] 2015 dulaglutide glargine 78 275 262”
Clinical efficacy and predictors of response to dulaglutide in type-2 diabetes
Berra, C., Resi, V., Mirani, M., Folini, L., Rossi, A., Solerte, S. B., & Fiorina, P. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104996 · Cited by 27
New Approaches to Feline Diabetes Mellitus: Glucagon-like peptide-1 analogs
Gilor, C., Rudinsky, A. J., & Hall, M. J. (2016) · Journal of Feline Medicine and Surgery · doi:10.1177/1098612x16660441 · Cited by 26
Metadata
- Authors
- Giorgino, F., Benroubi, M., Sun, J.-H., Zimmermann, A. G., & Pechtner, V.
- Affiliations
- University of Bari Aldo Moro (IT)
- Evangelismos-Polyclinic, Athens General Hospital, Athens, Greece
- Chang Gung Memorial Hospital (TW)
- Eli Lilly (United States) (US)
- Eli Lilly and Company, Neuilly-Sur-Seine Cedex, France
- Corresponding author
- Pechtner, Valeria
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2015-06-18
- Volume
- 38
- Issue
- 12
- Pages
- 2241-2249
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W906438903
- Cited by
- 268
- References
- 27
- Citations by year
- 2026: 16 · 2025: 29 · 2024: 17 · 2023: 20 · 2022: 19 · 2021: 21 · 2020: 22 · 2019: 28 · 2018: 29 · 2017: 27 · 2016: 23 · 2015: 17
- FWCI
- 27.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- dulaglutide, insulin glargine, type 2 diabetes, GLP-1 receptor agonists, metformin, glimepiride, HbA1c, glycemic control, non-inferiority, hypoglycemia, body weight, pancreatic enzymes, nausea, drug safety, dose comparison
- MeSH terms
- Insulin Glargine, Aged, Blood Glucose, Diabetes Mellitus, Type 2, Double-Blind Method, Glucagon-Like Peptides, Female, Gastrointestinal Diseases, Glycated Hemoglobin, Humans, Hypoglycemia, Hypoglycemic Agents, Immunoglobulin Fc Fragments, Male, Metformin, Middle Aged, Recombinant Fusion Proteins, Sulfonylurea Compounds, Weight Loss, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.